We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Novel Coating for Implants Could Prevent Premature Failure

By HospiMedica International staff writers
Posted on 14 May 2012
A nanoscale film for coating hip implants promotes bone growth, creating a stronger seal between the implants and the patients’ own bone. More...


Researchers at the Massachusetts Institute of Technology (MIT; Cambridge, USA) developed modular nanostructured multilayers--ranging from 100 nm to one µm--which contain hydroxyapatite (HA) particles in complex with the natural polymer chitosan, creating an osteoconductive surface for mesenchymal stem cells (MSCs). When coupled with the sustained release of physiological amounts of osteoinductive bone morphogenetic protein over several days from the degradable poly(β-amino ester) based multilayers, the single coating results in a synergistic accelerated and upregulated differentiation of MSCs into osteoblasts that lay down new bone tissue on orthopedic implants.

The thickness of the film and the amount of growth factor released are controlled by using a method called layer-by-layer assembly, in which the desired components are laid down one layer at a time until the desired thickness and drug composition are achieved. According to the researchers, the coating could be used not only for joint replacements, but also for fixation plates and screws or dental implants, thus reducing significantly the time needed to achieve osseointegration. The study was published in the March 15, 2012, issue of Advanced Materials.
“When bone cement is used, dead space is created between the existing bone and implant stem, where there are no blood vessels. If bacteria colonize this space they would keep proliferating, as the immune system is unable to reach and destroy them,” said lead author graduate student Nisarg Shah, BSc, and colleagues of the department of chemical engineering. “Our idea is to prevent failure by coating these implants with materials that can induce native bone that is generated within the body; that bone grows into the implant and helps fix it in place.”

Chitosan is derived from chitin, a polysaccharide found in the exoskeleton of shellfish such as shrimp, lobster, and or crabs. Chitosan's properties allow it to be used in transdermal drug delivery, since it is mucoadhesive in nature, reactive, and most importantly, its positive charge under acidic conditions leads to an increase in solubility. This means chitosan can be used to transport a drug to an acidic environment, where the chitosan packaging will then degrade, releasing the drug to the desired environment. One example of this drug delivery has been the transport of insulin.

Related Links:

Massachusetts Institute of Technology



Gold Member
POC Blood Gas Analyzer
Stat Profile Prime Plus
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Pressure Guidewire
SavvyWire
Electric Bed
DIXION Intensive Care Bed
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.